FORA Capital LLC Buys New Stake in Haleon plc (NYSE:HLN)

FORA Capital LLC purchased a new position in Haleon plc (NYSE:HLN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 96,992 shares of the company’s stock, valued at approximately $1,026,000.

Several other hedge funds and other institutional investors have also made changes to their positions in HLN. B. Riley Wealth Advisors Inc. increased its stake in Haleon by 23.2% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 29,324 shares of the company’s stock worth $246,000 after acquiring an additional 5,519 shares during the last quarter. Atria Investments Inc increased its position in Haleon by 5.7% in the first quarter. Atria Investments Inc now owns 181,557 shares of the company’s stock worth $1,541,000 after purchasing an additional 9,746 shares during the last quarter. Cetera Investment Advisers raised its stake in Haleon by 106.3% during the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock valued at $1,985,000 after purchasing an additional 120,447 shares in the last quarter. Cetera Advisors LLC lifted its position in Haleon by 524.3% during the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock valued at $696,000 after purchasing an additional 68,857 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Haleon by 13.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 16,204 shares of the company’s stock worth $138,000 after buying an additional 1,962 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Up 1.4 %

NYSE HLN opened at $9.72 on Friday. The stock has a market cap of $44.00 billion, a PE ratio of 28.59, a PEG ratio of 2.89 and a beta of 0.30. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company’s 50-day moving average price is $9.95 and its 200-day moving average price is $9.41. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HLN shares. Berenberg Bank assumed coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating for the company. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Finally, Morgan Stanley lifted their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.